These AEs are listed below with their rate of incidence in test subjects: Injection site reactions, like pruritus, rash, pain, and swelling (3.1%) Arthralgia (2.4%) Pain in the extremities (1.1%) Myalgia (1.1%) Peripheral edema (1.1%) Paresthesia (0.9%) Hypoesthesia (0.7%) Rash (0.7%) Dyspepsia (0.3%) Muscle pain (0.3%) Pruritus (0.3%) Vomiting (0.3%) Muscle stiffness (0.3%) Carpal Tunnel Syndrome (0.2%) Joint swelling (0.2%) Night sweats (0.2%) Palpitations (0.2%) Furthermore, clinical studies have linked tesamorelin to the following serious adverse events: Increased risk of glucose intolerance Increased risk of type 2 diabetes Disruption of hypothalamic-pituitary axis Neuropathies Lipoatrophy Diarrhea Fever Congestive heart failure Peripheral neuropathy Loss of mobility To date, no long-term tesamorelin studies involving healthy (non-elderly, non-HIV-infected) test subjects have been completed, suggesting that further research is merited
In summary, based on some weak animal data and essentially with no human evidence, BPC was claimed to be the mythical panacea for all ills
The flow rate was constant at 0.3 mL min 1 , the elution gradient was set as follows: 01.6 min 00 % B
Native IGF-1 has 10-20 minute half-life, strong IGFBP binding limiting bioavailability, primarily local autocrine/paracrine actions, and rapid clearance
